title: (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
abstract: BACKGROUND
  The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.
  
  
  METHODS
  PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of (64)Cu-DOTA-trastuzumab.
  
  
  RESULTS
  Metastatic brain lesions could be visualized by (64)Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.
  
  
  CONCLUSIONS
  Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.
  
  
  BACKGROUND
  UMIN000004170.
authors: Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
authors: Hiroaki
authors: H
authors: Kurihara
authors: Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan.
authors: Akinobu
authors: A
authors: Hamada
authors: Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan.
authors: Masayuki
authors: M
authors: Yoshida
authors: Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan.
authors: Schuichi
authors: S
authors: Shimma
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Jun
authors: J
authors: Hashimoto
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Kan
authors: K
authors: Yonemori
authors: Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan.
authors: Hitomi
authors: H
authors: Tani
authors: Department of Neurosurgery, National Cancer Center Hospital, Tokyo, Japan.
authors: Yasuji
authors: Y
authors: Miyakita
authors: RIKEN Center for Life Science Technologies, Hyogo, Japan.
authors: Yousuke
authors: Y
authors: Kanayama
authors: RIKEN Center for Life Science Technologies, Hyogo, Japan.
authors: Yasuhiro
authors: Y
authors: Wada
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Makoto
authors: M
authors: Kodaira
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Mayu
authors: M
authors: Yunokawa
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Harukaze
authors: H
authors: Yamamoto
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Chikako
authors: C
authors: Shimizu
authors: RIKEN Center for Life Science Technologies, Hyogo, Japan.
authors: Kazuhiro
authors: K
authors: Takahashi
authors: RIKEN Center for Life Science Technologies, Hyogo, Japan.
authors: Yasuyoshi
authors: Y
authors: Watanabe
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Yasuhiro
authors: Y
authors: Fujiwara
authors: Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Kenji
authors: K
authors: Tamura
keywords: 64Cu; Brain metastasis; HER2-positive breast cancer; PET; Trastuzumab